Introduction of BRCA testing in metastatic prostate cancer: a Belgian perspective
MSD and AstraZeneca Belgium are delighted to invite you to the virtual and interactive educational event:
Introduction of BRCA testing in metastatic prostate cancer: a Belgian perspective
Precision medicine has arrived for prostate cancer. Our webinar on the 1st of December will introduce you to PARP inhibitors and BRCA testing in metastatic prostate cancer. Both tissue and germline BRCA testing from a Belgian perspective will be discussed by our experts.
This webinar is intended for health care professionals only.
Virtual Interactive Webinar
Wednesday 1st of December 2021
19.30-20.45h
| Program | |
|---|---|
| 19h30-19h45 | PARPi as a new treatment option for metastatic castration resistant prostate cancer (Prof. Dr. Brieuc Sautois, CHU Liège) |
| 19h45-20h00 | A pathologist view on the implementation of tissue testing (Prof. Dr. Patrick Pauwels, UZA) |
| 20h00-20h15 | What about germline testing in clinical practice? (Dr. Robin De Putter, UZ Gent) |
| 20h15-20h45 | Q&A and panel discussion (Moderator: Prof. Dr. Brieuc Sautois, CHU Liège) |